Although chemotherapy can be effective in treating cancer, it can also exact a heavy toll on a patient’s health. One impressive alternative researchers have found is in the form of a vaccine. A type of immunotherapy, one part of the vaccine primes the body to react strongly against a tumor; the second part directly attacks the tumor itself. This double-pronged approach could be both more powerful against cancer and far less toxic to the body than traditional chemotherapy.
Don J. Diamond, Ph.D., director of the Division of Translational Vaccine Research, developed the anti-cancer vaccine in his lab with former colleague Joshua D.I. Ellenhorn, M.D. The vaccine consists of two parts: a vector, or carrier, virus, and an active agent that does the work. The carrier is a well-known, modified smallpox virus often used in research. The active agent — the real powerhouse in the vaccine — is the gene p53. Normally, p53 suppresses tumor growth. But in many cancer patients, the gene is mutated, allowing cancers to grow. The vaccine is designed to deliver normal, nonmutated versions of the gene to the body. » Continue Reading
The breast cancer statistic is attention-getting: One in eight women will be diagnosed with breast cancer during her lifetime. That doesn’t mean that, if you’re one of eight women at a dinner table, one of you is fated to have breast cancer (read more on that breast cancer statistic), but it does mean that the risk of developing breast cancer is not to be taken lightly. Neither is the decision on where to get breast cancer treatment.
As a nationally known biomedical research institution and as one of the nation’s few comprehensive cancer centers, City of Hope can provide access to therapies, research and clinical trials that other hospitals can’t.
Let’s start with clinical trials and research. The clinical trials available to City of Hope patients often stem from the research conducted on the City of Hope campus, where breast cancer specialists and researchers work together on therapies to improve survival and quality of life. Those clinical trials include assessments of new chemotherapy drugs, targeted therapies, hormone therapies, new surgical techniques and new radiation approaches — all focused on improving breast cancer treatment, detection and prevention. » Continue Reading
Advanced age tops the list among breast cancer risk factor for women. Not far behind is family history and genetics. Two City of Hope researchers delving deep into these issues recently received important grants to advance their studies.
Arti Hurria, M.D., director of the Cancer and Aging Research Program, and Jeffrey Weitzel, M.D., chief of the Division of Clinical Cancer Genetics, recently each received $240,000 in breast cancer grants from the Breast Cancer Research Foundation (BCRF). The studies aim to improve treatment and outcomes for older women and for Latino women at risk of hereditary breast cancer.
Breast cancer and age
Hurria’s renewal grant supports her efforts to understand how chemotherapy affects older adults with breast cancer. Even though women age 65 and older account for nearly half of all new U.S. breast cancer cases, little information is available to guide clinicians in their choices of chemotherapy for these women. » Continue Reading
City of Hope is extending the reach of its lifesaving mission well beyond U.S. borders. To that end, three distinguished City of Hope leaders visited China earlier this year to lay the foundation for the institution’s new International Medicine Program.
The program is part of City of Hope’s strategic efforts to grow its clinical programs and find innovative ways to expand access to its high-quality care to patients worldwide. The program is designed to attract and support international patients coming to City of Hope for care, with the initial focus on China.
Outreach abroad and locally
The trio of City of Hope ambassadors — Steven Rosen, M.D., provost, chief scientific officer, director of Beckman Research Institute of City of Hope and director of the comprehensive cancer center; Yuman Fong, M.D., chair of the Department of Surgery and director of the International Medicine Program; and David Horne, Ph.D., vice provost and associate director of Beckman Research Institute — journeyed to major Chinese research and treatment institutions to build relationships with physicians and researchers and educate them about the institution’s cancer expertise. » Continue Reading
Blueberries, cinnamon, baikal scullcap, grape seed extract (and grape skin extract), mushrooms, barberry, pomegranates … all contain compounds with the potential to treat, or prevent, cancer.
Scientists at City of Hope have found tantalizing evidence of this potential and are determined to explore it to the fullest. They’re researching, testing and developing new therapies made from nature’s bounty — from the vegetables, fruits and herbs many people take for granted as simply plants, not medicine.
To help them in their work, City of Hope has launched a Program in Natural Therapies, an effort to find more effective, but also less toxic, cancer therapies. The researchers have already made considerable progress. » Continue Reading
Most women who are treated for breast cancer with a mastectomy do not choose to undergo reconstructive surgery.
The reasons for this, according to a recent JAMA Surgery study, vary. Nearly half say they do not want any additional surgery, while nearly 34 percent say breast cancer reconstruction simply isn’t important to them. Fear of implants is another oft-cited factor, including worries that the implants might interfere with detection of recurrence – a fear cancer experts say is not founded.
The study also identified lack of access as a troubling issue. About 18 percent of women said they were not aware that breast cancer reconstruction was an option. Despite federal laws requiring that most group insurance plans that cover mastectomies also cover reconstructive surgery, 12 percent of women cited lack of insurance.
Laura Kruper, M.D., director of the Rita Cooper Finkel and J. William Finkel Women’s Health Center, acknowledges that many women will opt out of reconstructive surgery. However, with her patients, she stresses the importance of evaluating their options and weighing those choices very carefully. » Continue Reading
First, the good news: HIV infections have dropped dramatically over the past 30 years. Doctors, researchers and health officials have made great strides in preventing and treating the disease, turning what was once a death sentence into, for some, a chronic condition. Now, the reality check: HIV is still a worldwide health threat.
Worldwide, more than 34 million people are living with HIV or AIDs, and 1.1 million of those live in the United States.
City of Hope’s eighth annual San Gabriel Valley HIV/AIDS Action Summit brought together experts and activists to discuss, and help raise awareness of, the prevention, treatment and ultimate cure of HIV and AIDS.
Former State Assemblymember Anthony J. Portantino co-hosted the event, which included students from Duarte High School, Blair High School’s Health Careers Academy, CIS Academy in Pasadena, California, and the Applied Technology Center high school in Montebello.
Alexandra Levine, M.D., M.A.C.P., chief medical officer of City of Hope and deputy director for clinical programs of the cancer center, reflected on how far HIV/AIDS treatment has come even as she offered a stark reminder of today’s reality. Even though HIV is no longer a death sentence, she said, the disease is not to be taken lightly. » Continue Reading
Cancer cells are masters of survival. Despite excessive damage to their most basic workings and the constant vigilance of the body’s immune system, they manage to persevere.
Much of this extraordinary ability to survive falls under the control of proteins bearing the name STAT, short for signal transducer and activator of transcription. Prominent among these is STAT3. This protein helps shield tumor cells from the immune system. It also shuts down apoptosis, the process that normally forces sick cells to die, and it can help cancers spread through the body.
Hua Yu, Ph.D., the Billy and Audrey L Wilder Professor in Tumor Immmunotherapy and chair of the Department of Cancer Immunotherapeutics and Tumor Immunology at City of Hope, has made STAT3 the focus of much of her research. The first scientist to show for certain that STAT3 could be a molecular target for cancer therapy in animal models of the disease, she is widely regarded as a leader in the field, with numerous breakthrough discoveries surrounding the protein. That global leadership position recently received further affirmation when the Alexander von Humboldt Foundation elected her to receive the Humboldt Research Award. » Continue Reading
Here’s a statistic you’ll hear and read frequently over the next month: One in eight women born in the United States will develop breast cancer at some point in her lifetime.
Although this statement is accurate, based on breast cancer incidence rates in 2013, it’s often misunderstood.
Leslie Bernstein, Ph.D., director of cancer etiology at City of Hope, has spent much of her career researching cancer risk, including the factors linked to breast cancer and how risk can be reduced. What that statistic doesn’t mean, she says, is that if you’re gathered at dinner in a group of eight adult women, that one of you is going to develop breast cancer.
Bernstein sheds some light on the oft-repeated statistic: » Continue Reading